EZH2 and neoplasm: Specifically, in DMG where 80% of cases express the mutant H3K27M histone, focal gains of the H3K27me3 mark on critical tumor suppressors such as Cdkn2a [11] among others have been implied as an indirect consequence of residual EZH2 activity [32].